Here we report the development of a multispecific antibody optimized to efficiently overcome the multiple tumor escape mechanisms reported in hematological malignancies due to relapse from anti-CD38 mAb therapies6, while avoiding non-TAA directed CD47 targeting. This evidence concerns the gene CD38 and neoplasm.